Providers, Payors and Prior Authorization: A Second Front In Pricing Fight
Executive Summary
A below-the-radar effort to streamline prior authorization policies could have important implications for easing access to high-priced medicines. A new consensus statement aligns large provider groups with payors on some first principles.
You may also be interested in...
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.
Physicians Face Lengthy Waits For Drug Prior Authorization Reviews, Survey Finds
American Medical Association says its national physician survey shows preauthorization policies "negatively impact patient care."
Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D
The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.